GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cybin Inc (FRA:R7E) » Definitions » Net Income From Continuing Operations

Cybin (FRA:R7E) Net Income From Continuing Operations : €-53.52 Mil (TTM As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Cybin Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Cybin's net income from continuing operations for the three months ended in Jun. 2024 was €-10.05 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Jun. 2024 was €-53.52 Mil.

Cybin Net Income From Continuing Operations Historical Data

The historical data trend for Cybin's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cybin Net Income From Continuing Operations Chart

Cybin Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24
Net Income From Continuing Operations
- -21.53 -48.51 -32.42 -53.07

Cybin Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.08 -8.23 -20.73 -14.51 -10.05

Cybin Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-53.52 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cybin Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cybin Inc (FRA:R7E) » Definitions » Net Income From Continuing Operations
Comparable Companies
TSX:FRX TSX:SVA TSX:ONC NEOE:MMED TSX:EPRX XCNQ:DTC TSXV:NGEN TSX:BCT XCNQ:MSET TSXV:ARCH OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
CYBN:USA CYBN:Canada
Address
100 King Street West, Suite 5600, Toronto, ON, CAN, M5X 1C9
Website
https://www.cybin.com
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds and protocols as potential treatments for various psychiatric and neurological conditions.

Cybin Headlines

No Headlines